Veracyte, INC Form 4 insider transactions

CEO Marc Stapley reports acquisition of shares through PSU vesting and subsequent withholding for tax obligations.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., reports acquisition of shares through vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Rebecca Chambers, CFO of Veracyte, Inc., reports acquisition of shares through vesting of restricted stock units and subsequent withholding for tax obligations.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports acquisition of shares through vesting of performance-based restricted stock units and subsequent withholding of shares for tax obligations.

Rebecca Chambers, CFO of Veracyte, Inc., sold 527 shares of common stock at $43.85 per share on February 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Robert S. Epstein, a director at Veracyte, Inc., exercised stock options to acquire 20,000 shares of common stock at $8.04 per share on January 6, 2025.

Director Karin Eastham exercised stock options and sold shares of Veracyte, Inc. under a pre-arranged 10b5-1 trading plan.

Veracyte's CEO, Marc Stapley, sold a total of 5,590 shares of common stock on December 13, 2024, under a pre-arranged 10b5-1 trading plan.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., sold 3,934 shares of common stock at an average price of $44.0893 per share.

Annie McGuire, SVP and General Counsel at Veracyte, sold 18,699 shares of common stock at an average price of $44.0226 per share under a pre-arranged 10b5-1 trading plan.

Annie McGuire, SVP and General Counsel at Veracyte, Inc., reported the withholding of 1,918 shares of common stock to cover tax obligations related to vesting restricted stock units.

Veracyte's Chief Commercial Officer, John Leite, sold 1,050 shares of common stock at an average price of $43.2456, following the vesting of restricted stock units and a tax withholding event.

Veracyte's Chief Financial Officer, Rebecca Chambers, sold 7,000 shares of common stock at an average price of $43.2317, following the vesting of restricted stock units and associated tax withholdings.

Phillip G. Febbo, Chief Scientific & Medical Officer at Veracyte, Inc., reported a transaction involving the withholding of 6,738 common stock shares to cover tax obligations related to vesting restricted stock units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reported the disposal of shares to cover tax obligations and a sale of shares on December 2nd and 3rd, 2024.

Veracyte CEO Marc Stapley had shares withheld to cover tax obligations related to vesting restricted stock units, not representing a sale.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., sold 5,032 shares of common stock at an average price of $42.8922 on November 27, 2024.

Director Karin Eastham sold a total of 14,731 shares of Veracyte stock on November 19, 2024, under a pre-arranged 10b5-1 trading plan.

Veracyte's Chief Financial Officer, Rebecca Chambers, sold 15,275 shares of common stock at an average price of $38.3413 per share, as part of a pre-arranged 10b5-1 trading plan.

Veracyte director Robert S. Epstein exercised stock options and sold shares on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Director Evan Jones sold 5,173 shares of Veracyte (VCYT) common stock on September 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., sold 5,479 shares of common stock on September 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Rebecca Chambers, CFO of Veracyte, Inc., reports the withholding of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.

Veracyte's VP, Chief Accounting Officer Jonathan Wygant, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Veracyte's CEO, Marc Stapley, reports the withholding of common stock to cover tax obligations related to the vesting of restricted stock units.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Director Thomas F. Miller acquired 16,507 restricted stock units of Veracyte, Inc. on September 3, 2024.

Director David Brent Shafer of Veracyte, Inc. reports acquisition of 16,507 shares of common stock through restricted stock units.

Director Evan Jones reported multiple sales of Veracyte (VCYT) common stock and exercised stock options, executed under a pre-arranged 10b5-1 trading plan.